ID   RAD9A_HUMAN             Reviewed;         391 AA.
AC   Q99638; B2RCZ8; Q6FI29; Q96C41;
DT   07-MAR-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   15-MAR-2017, entry version 128.
DE   RecName: Full=Cell cycle checkpoint control protein RAD9A;
DE            Short=hRAD9;
DE            EC=3.1.11.2;
DE   AltName: Full=DNA repair exonuclease rad9 homolog A;
GN   Name=RAD9A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8943031; DOI=10.1073/pnas.93.24.13890;
RA   Lieberman H.B., Hopkins K.M., Nass M., Demetrick D., Davey S.;
RT   "A human homolog of the Schizosaccharomyces pombe rad9+ checkpoint
RT   control gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13890-13895(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PHE-3; ALA-100;
RP   ARG-239 AND THR-307.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 270-280; 326-329; 373-383 AND 385-390,
RP   IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION AT SER-272;
RP   SER-277; SER-328; SER-341; SER-375; SER-380 AND SER-387, AND
RP   MUTAGENESIS OF SER-272; SER-277; SER-328; SER-341; SER-375; SER-380
RP   AND SER-387.
RX   PubMed=12709442; DOI=10.1074/jbc.M301544200;
RA   Roos-Mattjus P., Hopkins K.M., Oestreich A.J., Vroman B.T.,
RA   Johnson K.L., Naylor S., Lieberman H.B., Karnitz L.M.;
RT   "Phosphorylation of human Rad9 is required for genotoxin-activated
RT   checkpoint signaling.";
RL   J. Biol. Chem. 278:24428-24437(2003).
RN   [8]
RP   INTERACTION WITH HUS1 AND RAD1.
RX   PubMed=10359610; DOI=10.1091/mbc.10.6.1985;
RA   St Onge R.P., Udell C.M., Casselman R., Davey S.;
RT   "The human G2 checkpoint control protein hRAD9 is a nuclear
RT   phosphoprotein that forms complexes with hRAD1 and hHUS1.";
RL   Mol. Biol. Cell 10:1985-1995(1999).
RN   [9]
RP   INTERACTION WITH HUS1 AND RAD1.
RX   PubMed=10777662; DOI=10.1006/geno.2000.6142;
RA   Hang H., Lieberman H.B.;
RT   "Physical interaction among human checkpoint control proteins HUS1p,
RT   RAD1p, and RAD9p, and implications for the regulation of cell cycle
RT   progression.";
RL   Genomics 65:24-33(2000).
RN   [10]
RP   FUNCTION IN EXONUCLEASE ACTIVITY.
RX   PubMed=10713044; DOI=10.1074/jbc.275.11.7451;
RA   Bessho T., Sancar A.;
RT   "Human DNA damage checkpoint protein hRAD9 is a 3' to 5'
RT   exonuclease.";
RL   J. Biol. Chem. 275:7451-7454(2000).
RN   [11]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH HDAC1.
RX   PubMed=10846170; DOI=10.1074/jbc.M000168200;
RA   Cai R.L., Yan-Neale Y., Cueto M.A., Xu H., Cohen D.;
RT   "HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two
RT   G2/M checkpoint Rad proteins.";
RL   J. Biol. Chem. 275:27909-27916(2000).
RN   [12]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH RAD17.
RX   PubMed=10884395; DOI=10.1074/jbc.M005782200;
RA   Rauen M., Burtelow M.A., Dufault V.M., Karnitz L.M.;
RT   "The human checkpoint protein hRad17 interacts with the PCNA-like
RT   proteins hRad1, hHus1, and hRad9.";
RL   J. Biol. Chem. 275:29767-29771(2000).
RN   [13]
RP   INTERACTION WITH DNAJC7.
RX   PubMed=11573955; DOI=10.1006/bbrc.2001.5685;
RA   Xiang S.L., Kumano T., Iwasaki S.I., Sun X., Yoshioka K.,
RA   Yamamoto K.C.;
RT   "The J domain of Tpr2 regulates its interaction with the proapoptotic
RT   and cell-cycle checkpoint protein, Rad9.";
RL   Biochem. Biophys. Res. Commun. 287:932-940(2001).
RN   [14]
RP   INTERACTION WITH ABL1 AND BCL2L1, PHOSPHORYLATION, PHOSPHORYLATION AT
RP   TYR-28, AND MUTAGENESIS OF TYR-28.
RX   PubMed=11971963; DOI=10.1128/MCB.22.10.3292-3300.2002;
RA   Yoshida K., Komatsu K., Wang H.-G., Kufe D.;
RT   "c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in
RT   response to DNA damage.";
RL   Mol. Cell. Biol. 22:3292-3300(2002).
RN   [15]
RP   INTERACTION WITH RAD9B.
RX   PubMed=14500360;
RA   Hopkins K.M., Wang X., Berlin A., Hang H., Thaker H.M.,
RA   Lieberman H.B.;
RT   "Expression of mammalian paralogues of HRAD9 and Mrad9 checkpoint
RT   control genes in normal and cancerous testicular tissue.";
RL   Cancer Res. 63:5291-5298(2003).
RN   [16]
RP   INTERACTION WITH PRKCD, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=12628935; DOI=10.1093/emboj/cdg134;
RA   Yoshida K., Wang H.-G., Miki Y., Kufe D.;
RT   "Protein kinase Cdelta is responsible for constitutive and DNA damage-
RT   induced phosphorylation of Rad9.";
RL   EMBO J. 22:1431-1441(2003).
RN   [17]
RP   ASSOCIATION OF THE 9-1-1 COMPLEX WITH THE RAD17-RFC COMPLEX, AND
RP   ELECTRON MICROSCOPY OF THE 9-1-1 AND RAD17-RFC COMPLEXES BOUND TO DNA.
RX   PubMed=12578958; DOI=10.1073/pnas.0437927100;
RA   Bermudez V.P., Lindsey-Boltz L.A., Cesare A.J., Maniwa Y.,
RA   Griffith J.D., Hurwitz J., Sancar A.;
RT   "Loading of the human 9-1-1 checkpoint complex onto DNA by the
RT   checkpoint clamp loader hRad17-replication factor C complex in
RT   vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:1633-1638(2003).
RN   [18]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH POLB.
RX   PubMed=15314187; DOI=10.1093/nar/gkh652;
RA   Toueille M., El-Andaloussi N., Frouin I., Freire R., Funk D.,
RA   Shevelev I., Friedrich-Heineken E., Villani G., Hottiger M.O.,
RA   Huebscher U.;
RT   "The human Rad9/Rad1/Hus1 damage sensor clamp interacts with DNA
RT   polymerase beta and increases its DNA substrate utilisation
RT   efficiency: implications for DNA repair.";
RL   Nucleic Acids Res. 32:3316-3324(2004).
RN   [19]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH FEN1.
RX   PubMed=15556996; DOI=10.1073/pnas.0407686101;
RA   Wang W., Brandt P., Rossi M.L., Lindsey-Boltz L., Podust V.,
RA   Fanning E., Sancar A., Bambara R.A.;
RT   "The human Rad9-Rad1-Hus1 checkpoint complex stimulates flap
RT   endonuclease 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:16762-16767(2004).
RN   [20]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH LIG1.
RX   PubMed=15871698; DOI=10.1042/BJ20050211;
RA   Smirnova E., Toueille M., Markkanen E., Huebscher U.;
RT   "The human checkpoint sensor and alternative DNA clamp Rad9-Rad1-Hus1
RT   modulates the activity of DNA ligase I, a component of the long-patch
RT   base excision repair machinery.";
RL   Biochem. J. 389:13-17(2005).
RN   [21]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH FEN1, AND
RP   INTERACTION WITH FEN1.
RX   PubMed=16216273; DOI=10.1016/j.jmb.2005.09.018;
RA   Friedrich-Heineken E., Toueille M., Taennler B., Buerki C.,
RA   Ferrari E., Hottiger M.O., Huebscher U.;
RT   "The two DNA clamps Rad9/Rad1/Hus1 complex and proliferating cell
RT   nuclear antigen differentially regulate flap endonuclease 1
RT   activity.";
RL   J. Mol. Biol. 353:980-989(2005).
RN   [22]
RP   IDENTIFICATION IN THE 9-1-1 COMPLEX ASSOCIATED WITH RPA1 AND RPA2, AND
RP   INTERACTION WITH RPA1 AND RPA2.
RX   PubMed=15897895; DOI=10.1038/sj.onc.1208674;
RA   Wu X., Shell S.M., Zou Y.;
RT   "Interaction and colocalization of Rad9/Rad1/Hus1 checkpoint complex
RT   with replication protein A in human cells.";
RL   Oncogene 24:4728-4735(2005).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375; SER-380 AND
RP   SER-387, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277 AND SER-387, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277; SER-375 AND
RP   SER-387, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277; SER-375 AND
RP   SER-387, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-387, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [30]
RP   FUNCTION, INTERACTION WITH RHNO1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=21659603; DOI=10.1126/science.1203430;
RA   Cotta-Ramusino C., McDonald E.R. III, Hurov K., Sowa M.E.,
RA   Harper J.W., Elledge S.J.;
RT   "A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1
RT   interacting protein required for ATR signaling.";
RL   Science 332:1313-1317(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328 AND SER-387, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Component of the 9-1-1 cell-cycle checkpoint response
CC       complex that plays a major role in DNA repair. The 9-1-1 complex
CC       is recruited to DNA lesion upon damage by the RAD17-replication
CC       factor C (RFC) clamp loader complex. Acts then as a sliding clamp
CC       platform on DNA for several proteins involved in long-patch base
CC       excision repair (LP-BER). The 9-1-1 complex stimulates DNA
CC       polymerase beta (POLB) activity by increasing its affinity for the
CC       3'-OH end of the primer-template and stabilizes POLB to those
CC       sites where LP-BER proceeds; endonuclease FEN1 cleavage activity
CC       on substrates with double, nick, or gap flaps of distinct
CC       sequences and lengths; and DNA ligase I (LIG1) on long-patch base
CC       excision repair substrates. The 9-1-1 complex is necessary for the
CC       recruitment of RHNO1 to sites of double-stranded breaks (DSB)
CC       occurring during the S phase. RAD9A possesses 3'->5' double
CC       stranded DNA exonuclease activity. Its phosphorylation by PRKCD
CC       may be required for the formation of the 9-1-1 complex.
CC       {ECO:0000269|PubMed:10713044, ECO:0000269|PubMed:21659603}.
CC   -!- CATALYTIC ACTIVITY: Exonucleolytic cleavage in the 3'- to 5'-
CC       direction to yield nucleoside 5'-phosphates.
CC   -!- SUBUNIT: Component of the toroidal 9-1-1 (RAD9-RAD1-HUS1) complex,
CC       composed of RAD9A, RAD1 and HUS1. The 9-1-1 complex associates
CC       with LIG1, POLB, FEN1, RAD17, HDAC1, RPA1 and RPA2. The 9-1-1
CC       complex associates with the RAD17-RFC complex. RAD9A interacts
CC       with BCL2L1, FEN1, PRKCD, RAD9B, HUS1, RAD1, ABL1, RPA1, ATAD5 and
CC       RPA2. Interacts with DNAJC7 and RHNO1.
CC       {ECO:0000269|PubMed:10359610, ECO:0000269|PubMed:10777662,
CC       ECO:0000269|PubMed:10846170, ECO:0000269|PubMed:10884395,
CC       ECO:0000269|PubMed:11573955, ECO:0000269|PubMed:11971963,
CC       ECO:0000269|PubMed:12628935, ECO:0000269|PubMed:14500360,
CC       ECO:0000269|PubMed:15314187, ECO:0000269|PubMed:15556996,
CC       ECO:0000269|PubMed:15871698, ECO:0000269|PubMed:15897895,
CC       ECO:0000269|PubMed:16216273, ECO:0000269|PubMed:21659603}.
CC   -!- INTERACTION:
CC       O60921:HUS1; NbExp=9; IntAct=EBI-2606224, EBI-1056174;
CC       O60671:RAD1; NbExp=2; IntAct=EBI-2606224, EBI-721835;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12628935}.
CC   -!- PTM: Constitutively phosphorylated on serine and threonine amino
CC       acids in absence of DNA damage. Hyperphosphorylated by PRKCD and
CC       ABL1 upon DNA damage. Its phosphorylation by PRKCD may be required
CC       for the formation of the 9-1-1 complex.
CC       {ECO:0000269|PubMed:11971963, ECO:0000269|PubMed:12628935,
CC       ECO:0000269|PubMed:12709442}.
CC   -!- SIMILARITY: Belongs to the rad9 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/rad9a/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RAD9AID42031ch11q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U53174; AAB39928.1; -; mRNA.
DR   EMBL; CR536508; CAG38746.1; -; mRNA.
DR   EMBL; AY766122; AAU89725.1; -; Genomic_DNA.
DR   EMBL; AK315348; BAG37745.1; -; mRNA.
DR   EMBL; CH471076; EAW74605.1; -; Genomic_DNA.
DR   EMBL; BC014848; AAH14848.1; -; mRNA.
DR   CCDS; CCDS8159.1; -.
DR   RefSeq; NP_001230153.1; NM_001243224.1.
DR   RefSeq; NP_004575.1; NM_004584.2.
DR   UniGene; Hs.655354; -.
DR   PDB; 3A1J; X-ray; 2.50 A; A=1-266.
DR   PDB; 3G65; X-ray; 2.90 A; A=1-270.
DR   PDB; 3GGR; X-ray; 3.20 A; A=1-270.
DR   PDBsum; 3A1J; -.
DR   PDBsum; 3G65; -.
DR   PDBsum; 3GGR; -.
DR   ProteinModelPortal; Q99638; -.
DR   SMR; Q99638; -.
DR   BioGrid; 111820; 32.
DR   DIP; DIP-24255N; -.
DR   DIP; DIP-40930N; -.
DR   IntAct; Q99638; 7.
DR   MINT; MINT-134869; -.
DR   STRING; 9606.ENSP00000311360; -.
DR   iPTMnet; Q99638; -.
DR   PhosphoSitePlus; Q99638; -.
DR   BioMuta; RAD9A; -.
DR   DMDM; 74717382; -.
DR   EPD; Q99638; -.
DR   MaxQB; Q99638; -.
DR   PaxDb; Q99638; -.
DR   PeptideAtlas; Q99638; -.
DR   PRIDE; Q99638; -.
DR   Ensembl; ENST00000307980; ENSP00000311360; ENSG00000172613.
DR   GeneID; 5883; -.
DR   KEGG; hsa:5883; -.
DR   UCSC; uc001okr.4; human.
DR   CTD; 5883; -.
DR   DisGeNET; 5883; -.
DR   GeneCards; RAD9A; -.
DR   HGNC; HGNC:9827; RAD9A.
DR   HPA; HPA006725; -.
DR   HPA; HPA048155; -.
DR   MIM; 603761; gene.
DR   neXtProt; NX_Q99638; -.
DR   OpenTargets; ENSG00000172613; -.
DR   PharmGKB; PA294; -.
DR   eggNOG; KOG2810; Eukaryota.
DR   eggNOG; ENOG410XYYN; LUCA.
DR   GeneTree; ENSGT00390000005767; -.
DR   HOGENOM; HOG000059650; -.
DR   HOVERGEN; HBG058989; -.
DR   InParanoid; Q99638; -.
DR   KO; K10994; -.
DR   OMA; LHCKHGL; -.
DR   OrthoDB; EOG091G0B2E; -.
DR   PhylomeDB; Q99638; -.
DR   TreeFam; TF101212; -.
DR   Reactome; R-HSA-176187; Activation of ATR in response to replication stress.
DR   Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA).
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   SignaLink; Q99638; -.
DR   SIGNOR; Q99638; -.
DR   ChiTaRS; RAD9A; human.
DR   EvolutionaryTrace; Q99638; -.
DR   GeneWiki; RAD9A; -.
DR   GenomeRNAi; 5883; -.
DR   PRO; PR:Q99638; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000172613; -.
DR   CleanEx; HS_RAD9A; -.
DR   ExpressionAtlas; Q99638; baseline and differential.
DR   Genevisible; Q99638; HS.
DR   GO; GO:0030896; C:checkpoint clamp complex; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008408; F:3'-5' exonuclease activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0008853; F:exodeoxyribonuclease III activity; IEA:UniProtKB-EC.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IDA:UniProtKB.
DR   GO; GO:0000077; P:DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IBA:GO_Central.
DR   GO; GO:0006260; P:DNA replication; TAS:Reactome.
DR   GO; GO:0000076; P:DNA replication checkpoint; TAS:ProtInc.
DR   GO; GO:0031573; P:intra-S DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:1902231; P:positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   InterPro; IPR026584; Rad9.
DR   InterPro; IPR007268; Rad9/Ddc1.
DR   PANTHER; PTHR15237; PTHR15237; 1.
DR   Pfam; PF04139; Rad9; 1.
DR   PIRSF; PIRSF009303; Cell_cycle_RAD9; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Direct protein sequencing;
KW   DNA damage; Exonuclease; Hydrolase; Nuclease; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome.
FT   CHAIN         1    391       Cell cycle checkpoint control protein
FT                                RAD9A.
FT                                /FTId=PRO_0000225000.
FT   REGION       51     91       Possesses 3'-5' exonuclease activity.
FT   REGION      266    391       Sufficient for interaction with ABL1.
FT                                {ECO:0000269|PubMed:11971963}.
FT   MOD_RES      28     28       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:11971963}.
FT   MOD_RES     272    272       Phosphoserine.
FT                                {ECO:0000269|PubMed:12709442}.
FT   MOD_RES     277    277       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000269|PubMed:12709442}.
FT   MOD_RES     328    328       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:12709442}.
FT   MOD_RES     341    341       Phosphoserine.
FT                                {ECO:0000269|PubMed:12709442}.
FT   MOD_RES     375    375       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000269|PubMed:12709442}.
FT   MOD_RES     380    380       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000269|PubMed:12709442}.
FT   MOD_RES     387    387       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:12709442}.
FT   VARIANT       3      3       C -> F (in dbSNP:rs11575913).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025410.
FT   VARIANT      71     71       L -> Q (in dbSNP:rs2422490).
FT                                /FTId=VAR_051724.
FT   VARIANT     100    100       S -> A (in dbSNP:rs2066492).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025411.
FT   VARIANT     239    239       H -> R (in dbSNP:rs17880039).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025412.
FT   VARIANT     307    307       M -> T (in dbSNP:rs17882466).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_025413.
FT   MUTAGEN      28     28       Y->F: Abolishes phosphorylation by ABL1.
FT                                {ECO:0000269|PubMed:11971963}.
FT   MUTAGEN     272    272       S->A: Complete loss of phosphorylation
FT                                and no loss of interaction with the 9-1-1
FT                                complex; when associated with A-277; A-
FT                                328; A-341; A-375; A-380 and A-387.
FT                                {ECO:0000269|PubMed:12709442}.
FT   MUTAGEN     277    277       S->A: Complete loss of phosphorylation
FT                                and no loss of interaction with the 9-1-1
FT                                complex; when associated with A-272; A-
FT                                328; A-341; A-375; A-380 and A-387.
FT                                {ECO:0000269|PubMed:12709442}.
FT   MUTAGEN     328    328       S->A: Complete loss of phosphorylation
FT                                and no loss of interaction with the 9-1-1
FT                                complex; when associated with A-272; A-
FT                                277; A-341; A-375; A-380 and A-387.
FT                                {ECO:0000269|PubMed:12709442}.
FT   MUTAGEN     341    341       S->A: Complete loss of phosphorylation
FT                                and no loss of interaction with the 9-1-1
FT                                complex; when associated with A-272; A-
FT                                277; A-328; A-375; A-380 and A-387.
FT                                {ECO:0000269|PubMed:12709442}.
FT   MUTAGEN     375    375       S->A: Complete loss of phosphorylation
FT                                and no loss of interaction with the 9-1-1
FT                                complex; when associated with A-272; A-
FT                                277; A-328; A-341; A-380 and A-387.
FT                                {ECO:0000269|PubMed:12709442}.
FT   MUTAGEN     380    380       S->A: Complete loss of phosphorylation
FT                                and no loss of interaction with the 9-1-1
FT                                complex; when associated with A-272; A-
FT                                277; A-328; A-341; A-375 and A-387.
FT                                {ECO:0000269|PubMed:12709442}.
FT   MUTAGEN     387    387       S->A: Complete loss of phosphorylation
FT                                and no loss of interaction with the 9-1-1
FT                                complex; when associated with A-272; A-
FT                                277; A-328; A-341; A-375 and A-380.
FT                                {ECO:0000269|PubMed:12709442}.
FT   CONFLICT     12     12       V -> A (in Ref. 2; CAG38746).
FT                                {ECO:0000305}.
FT   CONFLICT    130    130       E -> A (in Ref. 6; AAH14848).
FT                                {ECO:0000305}.
FT   STRAND        2      6       {ECO:0000244|PDB:3A1J}.
FT   HELIX         8     21       {ECO:0000244|PDB:3A1J}.
FT   STRAND       25     32       {ECO:0000244|PDB:3A1J}.
FT   STRAND       35     41       {ECO:0000244|PDB:3A1J}.
FT   STRAND       47     53       {ECO:0000244|PDB:3A1J}.
FT   HELIX        55     57       {ECO:0000244|PDB:3A1J}.
FT   STRAND       58     62       {ECO:0000244|PDB:3A1J}.
FT   STRAND       66     68       {ECO:0000244|PDB:3A1J}.
FT   STRAND       73     76       {ECO:0000244|PDB:3A1J}.
FT   HELIX        77     84       {ECO:0000244|PDB:3A1J}.
FT   HELIX        87     93       {ECO:0000244|PDB:3A1J}.
FT   STRAND       94    100       {ECO:0000244|PDB:3A1J}.
FT   STRAND      106    114       {ECO:0000244|PDB:3A1J}.
FT   HELIX       115    117       {ECO:0000244|PDB:3A1J}.
FT   STRAND      119    125       {ECO:0000244|PDB:3A1J}.
FT   HELIX       138    140       {ECO:0000244|PDB:3A1J}.
FT   STRAND      142    148       {ECO:0000244|PDB:3A1J}.
FT   HELIX       149    156       {ECO:0000244|PDB:3A1J}.
FT   STRAND      165    170       {ECO:0000244|PDB:3A1J}.
FT   HELIX       172    174       {ECO:0000244|PDB:3A1J}.
FT   STRAND      176    181       {ECO:0000244|PDB:3A1J}.
FT   STRAND      187    189       {ECO:0000244|PDB:3GGR}.
FT   STRAND      194    199       {ECO:0000244|PDB:3A1J}.
FT   HELIX       201    203       {ECO:0000244|PDB:3A1J}.
FT   STRAND      205    208       {ECO:0000244|PDB:3A1J}.
FT   STRAND      214    218       {ECO:0000244|PDB:3A1J}.
FT   HELIX       219    231       {ECO:0000244|PDB:3A1J}.
FT   STRAND      235    240       {ECO:0000244|PDB:3A1J}.
FT   STRAND      241    245       {ECO:0000244|PDB:3GGR}.
FT   STRAND      247    252       {ECO:0000244|PDB:3A1J}.
FT   STRAND      254    262       {ECO:0000244|PDB:3A1J}.
FT   STRAND      267    269       {ECO:0000244|PDB:3G65}.
SQ   SEQUENCE   391 AA;  42547 MW;  4D4D6D4C6E1057D3 CRC64;
     MKCLVTGGNV KVLGKAVHSL SRIGDELYLE PLEDGLSLRT VNSSRSAYAC FLFAPLFFQQ
     YQAATPGQDL LRCKILMKSF LSVFRSLAML EKTVEKCCIS LNGRSSRLVV QLHCKFGVRK
     THNLSFQDCE SLQAVFDPAS CPHMLRAPAR VLGEAVLPFS PALAEVTLGI GRGRRVILRS
     YHEEEADSTA KAMVTEMCLG EEDFQQLQAQ EGVAITFCLK EFRGLLSFAE SANLNLSIHF
     DAPGRPAIFT IKDSLLDGHF VLATLSDTDS HSQDLGSPER HQPVPQLQAH STPHPDDFAN
     DDIDSYMIAM ETTIGNEGSR VLPSISLSPG PQPPKSPGPH SEEEDEAEPS TVPGTPPPKK
     FRSLFFGSIL APVRSPQGPS PVLAEDSEGE G
//
